BI 764532: DLL3/CD3 T-cell engager | ep-NEC

Clinical research has shown that the current wave of checkpoint-centric therapies is beneficial in those patients with immunologically active and highly-mutated so-called ‘hot’ tumors. But they have limited efficacy in those tumor types that lack these properties, commonly known as ‘cold’ tumors. Boehringer Ingelheim has made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers. We are developing complementary platforms including T-cell engagers, oncolytic viruses, and cancer vaccines, which have the potential to turn cold tumors hot, extending the benefits of immunotherapy to more people.

 

T-cell engagers are targeted immunotherapeutics, which can directly reactivate T-cells, potentially resulting in the selective killing of tumor cells by the body’s own immune system.

 

This compound is under investigation, further information will be available soon.